FNFrancesco Nai

Francesco Nai

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Francesco Nai has a total of 54 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Structure-Based Design of Potent Pan-YTHDF Ligands

    by Francesco Errani, Francesco Nai, Elena Bochenkova, Marcin Herok, Annalisa Invernizzi, Rajiv Kumar Bedi, Yaozong Li, FrantišeK ZálEšák, Amedeo Caflisch

    The reader proteins YTHDF1-3 recognize m6A-RNA in the cytosol. Here, we present a structure-based medicinal chemistry campaign that culminated in the pan-YTHDF inhibitor 34 (Kd = 0.14 μM for YTHDF2 by calorimetry), which is selective against YTHDC1 and YTHDC2. The high-resolution crystal structures of the complex of YTHDF2 with six members of the series validate the structure-based design. Using the structural information, we designed compound 31 (IC50 = 0.22 μM for YTHDF2) and a negative control, i.e., its methylated analogue 31b. The cellular thermal shift assay provides evidence of YTHDF2 target engagement in cells for inhibitors 34 and 31, while the negative control 31b is inactive. Compounds 34 and 31 inhibit the proliferation of the AML cell lines MOLM-13 and THP-1. The inhibition of the YTHDF readers by 31 increases the level and stability of the transcript of TNFRSF1B. This renders THP-1 cells more sensitive to TNF-α-induced toxicity.

  • Open Access

    Adenosine 5′-Carboxamide-Based Inhibitors of METTL1

    by Olga Bobileva, Francesco Nai, Sandija Niedrite, Lidia Mayordomo Soler, Irena Leite, Amedeo Caflisch

    METTL1 is the human RNA methyltransferase that catalyzes the methylation of N7-guanosine in RNA. Overexpression of METTL1 has been linked to cancer, and increasing evidence supports the therapeutic potential of METTL1 inhibition in oncology. In this study, we have optimized a series of adenosine 5′-carboxamide derivatives as METTL1 inhibitors through structure-guided modifications of a previously discovered hit compound. The advanced inhibitor B22 shows an IC50 of 1 μM in an enzymatic assay, which is a 178-fold improvement with respect to the initial hit. The crystal structure of the des-methyl analogue of B22 (compound B19, IC50 = 0.4 μM) provides evidence that the benzylpiperazine moiety is accommodated within the guanosine-binding subsite of METTL1. The inhibitor B22 shows high solubility and metabolic stability and is selective against a panel of seven histone methyltransferases and the RNA-methyltransferase METTL3/METTL14.


  • Targeting the METTL1/m7G axis as a therapeutic strategy in myeloid leukemia

    by Lili Ren, Honghai Zhang, Olga Bobileva, Francesco Nai, Hongjie Bi, Anthony Chan, Genevieve E. Baker, Lei Dong, David Guarin, Weidong Hu, et al.

    N7-methylguanosine (m7G), a prevalent modification in transfer RNAs (tRNAs), is primarily catalyzed by the methyltransferase METTL1. Although growing evidence supports a role for METTL1 in various tumors, its therapeutic potential and precise function in leukemia stem cell (LSC) homeostasis remain largely unexplored. Here, we identify METTL1 as a key regulator of LSC self-renewal and homing within bone marrow (BM) microenvironment through catalyzing m7G formation on a specific tRNA, tRNAPheGAA, thereby promoting leukemogenesis. Mechanistically, METTL1 loss significantly reduces m7G abundance and steady-state levels of tRNAPheGAA, leading to translation suppression and degradation of transcripts enriched with tRNAPheGAA-related codons, such as hematopoietic cell kinase (HCK). Decreased HCK expression disrupts CXCR4 signaling, impairing LSC self-renewal and BM homing. Therapeutically, we characterized a small-molecule METTL1 inhibitor (M1i; NSC137443), through high-throughput screening. Pharmacological inhibition of METTL1 demonstrated potent antitumor efficacy by reducing tRNA m7G levels and disrupting the tRNAPheGAA/HCK/CXCR4 cascade. Notably, targeting METTL1 significantly reduces LSC frequency, delays leukemogenesis, and prolongs survival in multiple acute myeloid leukemia models. Together, our findings establish a previously unrecognized role for METTL1 and its target tRNAPheGAA in LSC homeostasis and provide compelling proof-of-concept evidence that METTL1 is a druggable epitranscriptomic target for antileukemia therapy.


  • Open Access

    Discovery of YTHDF2 Ligands by Fragment-Based Design

    by Annalisa Invernizzi, Francesco Nai, Rajiv Kumar Bedi, Pablo Andrés Vargas-Rosales, Yaozong Li, Elena Bochenkova, Marcin Herok, František Zálešák, Amedeo Caflisch

    N 6-Adenosine methylation is the most abundant modification of mRNA. The three members of the YTH domain family proteins (YTHDF1–3) recognize in the cytoplasm the m6A-RNA modification. We screened a library of about 500,000 fragments (i.e., molecules with 11–20 non-hydrogen atoms) by docking into YTHDF2, which resulted in the identification of six active compounds among 47 tested in vitro (hit rate of 13%). The acquisition of 28 analogues of the docking hits provided an additional set of 10 active compounds (IC50 < 100 μM). Protein crystallography-guided optimization of a ligand-efficient fragment by the synthesis of 32 derivatives culminated in a series of YTHDF2 ligands, which show low-micromolar affinity measured by a fluorescence polarization (FP) assay and a homogeneous time-resolved fluorescence-based (HTRF) assay. The series is characterized by very favorable ligand efficiency (of about 0.3–0.4 kcal/mol per non-hydrogen atom). Compound 23 binds to YTHDF2 according to the FP and HTRF assays with a K d value of 1.3 μM and an IC50 value of 11 μM, respectively, and it is selective against all of the other YTH reader proteins. Several compounds of the series bind to the three YTHDF proteins with similar low-micromolar affinity, while they are less potent for YTHDC1 and YTHDC2. In contrast, compounds 17 and 30 bind also to YTHDC2, with K d of 6.3 and 4.9 μM, respectively. We also disclose six crystal structures of YTHDF2 in the complex with the fragments identified by docking.


  • Open Access

    Structure-Based Design of a Potent and Selective YTHDC1 Ligand

    by František Zálešák, Francesco Nai, Marcin Herok, Elena Bochenkova, Rajiv K. Bedi, Yaozong Li, Francesco Errani, Amedeo Caflisch

    N6-Adenosine methylation (m6A) is a prevalent post-transcriptional modification of mRNA, with YTHDC1 being the reader protein responsible for recognizing this modification in the cell nucleus. Here, we present a protein structure-based medicinal chemistry campaign that resulted in the YTHDC1 inhibitor 40, which shows an equilibrium dissociation constant (Kd) of 49 nM. The crystal structure of the complex (1.6 Å resolution) validated the design. Compound 40 is selective against the cytoplasmic m6A-RNA readers YTHDF1-3 and YTHDC2 and shows antiproliferative activity against the acute myeloid leukemia (AML) cell lines THP-1, MOLM-13, and NOMO-1. For the series of compounds that culminated into ligand 40, the good correlation between the affinity in the biochemical assay and antiproliferative activity in the THP-1 cell line provides evidence of YTHDC1 target engagement in the cell. The binding to YTHDC1 in the cell is further supported by the cellular thermal shift assay. Thus, ligand 40 is a tool compound for studying the role of YTHDC1 in AML.


  • Open Access

    Small-Molecule Inhibitors of the m7G-RNA Writer METTL1

    by Francesco Nai, Maria Paula Flores Espinoza, Annalisa Invernizzi, Pablo Andrés Vargas-Rosales, Olga Bobileva, Marcin Herok, Amedeo Caflisch

    We discovered the first inhibitors of the m7G-RNA writer METTL1 by high-throughput docking and an enzymatic assay based on luminescence. Eleven compounds, which belong to three different chemotypes, show inhibitory activity in the range 40-300 μM. Two adenine derivatives identified by docking have very favorable ligand efficiency of 0.34 and 0.31 kcal/mol per non-hydrogen atom, respectively. Molecular dynamics simulations provide evidence that the inhibitors compete with the binding of the cosubstrate S-adenosyl methionine to METTL1. We also present a soakable crystal form that was used to determine the structure of the complex of METTL1 with sinefungin at a resolution of 1.85 Å.


  • Open Access

    Fragment Ligands of the m6A-RNA Reader YTHDF2

    by Francesco Nai, Raed Nachawati, František Zálešák, Xiang Wang, Yaozong Li, Amedeo Caflisch

    We report 17 small-molecule ligands that compete with N6-methyladenosine (m6A) for binding to the m6A-reader domain of YTHDF2 (YT521-B homology domain family 2). We determined their binding mode at high resolution by X-ray crystallography and quantified their affinity by a fluorescence-based binding assay. 6-Cyclopropyluracil and a pyrazolopyrimidine derivative have favorable ligand efficiencies of 0.47 and 0.38 kcal mol-1 per non-hydrogen atom, respectively. They represent useful starting points for hit optimization.


  • Open Access

    Structure-based design of ligands of the m6A-RNA reader YTHDC1

    by Yaozong Li, Rajiv Kumar Bedi, Francesco Nai, Valentin von Roten, Aymeric Dolbois, František Zálešák, Raed Nachawati, Danzhi Huang, Amedeo Caflisch